Department of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon 21431, Korea.
Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Gyeonggi-do 14647, Korea.
Int J Mol Sci. 2020 Sep 24;21(19):7041. doi: 10.3390/ijms21197041.
Psoriasis and psoriatic arthritis (PsA) have been recently considered as chronic systemic inflammatory disorders. Over the past decades, enormous evidence indicates that patients with psoriasis and PsA have a higher risk of developing various comorbidities including cardiovascular disease, metabolic disease, cancers, infections, autoimmune disease, and psychiatric diseases. However, reported risks of some comorbidities in those with psoriasis and PsA are somewhat different according to the research design. Moreover, pathomechanisms underlying comorbidities of those with psoriasis and PsA remain poorly elucidated. The purpose of this review is to provide the most updated comprehensive view of the risk of systemic comorbidities in those with psoriasis and PsA. Molecular mechanisms associated with the development of various comorbidities in those with psoriasis and PsA are also reviewed based on recent laboratory and clinical investigations. Identifying the risk of systemic comorbidities and its associated pathomechanisms in those with psoriasis and PsA could provide a sufficient basis to use a multi-disciplinary approach for treating patients with psoriasis and PsA.
银屑病和银屑病关节炎（PsA）最近被认为是慢性系统性炎症性疾病。过去几十年来，大量证据表明，银屑病和 PsA 患者发生各种合并症的风险更高，包括心血管疾病、代谢疾病、癌症、感染、自身免疫性疾病和精神疾病。然而，根据研究设计的不同，银屑病和 PsA 患者的某些合并症的报告风险有所不同。此外，银屑病和 PsA 患者合并症的发病机制仍不清楚。本综述的目的是提供关于银屑病和 PsA 患者发生全身合并症风险的最新全面观点。还根据最近的实验室和临床研究，综述了与银屑病和 PsA 患者各种合并症发展相关的分子机制。确定银屑病和 PsA 患者发生全身合并症的风险及其相关发病机制，可以为采用多学科方法治疗银屑病和 PsA 患者提供充分的依据。
Zotero 插件